Skip to main content
SpringerLink
Log in

Budesonide/formoterol Easyhaler®: a guide to its use in asthma and chronic obstructive pulmonary disease

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Budesonide/formoterol Easyhaler® is an easy-to-use, convenient, effective and well tolerated option for the treatment of patients with asthma or chronic obstructive pulmonary disease (COPD). This device-metered dry powder inhaler (DPI) contains both the inhaled corticosteroid budesonide and the long-acting β2-adrenoceptor agonist formoterol. The use of the budesonide/formoterol in a single inhaler is well established as an effective and well tolerated option for the treatment of asthma and COPD. Budesonide/formoterol Easyhaler® is therapeutically equivalent to budesonide/formoterol Turbuhaler®, and is indicated for use as maintenance therapy in adults, adolescents and children aged ≥6 years with asthma, maintenance and reliever therapy in adults with asthma and for the symptomatic treatment of adults with severe COPD and a history of repeated exacerbations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Global Initiative for Asthma. Global strategy for asthma management and prevention (updated 2016). http://www.ginasthma.org. Accessed 10 Jan 2017.

  2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2017 report). http://www.goldcopd.org. Accessed 10 Jan 2017.

  3. Kew KM, Karner C, Mindus SM, et al. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;12:CD009019.

    Google Scholar 

  4. Bufomix Easyhaler 80 micrograms/4.5 micrograms. Dublin: Orion Pharma (Ireland) Ltd; 2016.

  5. Lindberg A, Szalai Z, Pullerits T, et al. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology. 2007;12(5):732–9.

    Article  PubMed  Google Scholar 

  6. Malmberg LP, Everard ML, Haikarainen J, et al. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler®. J Aerosol Med Pulm Drug Deliv. 2014;27(5):329–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. European Medicines Agency. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD). 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003508.pdf. Accessed 10 Jan 2017.

  8. Chrystyn H. Closer to an ‘ideal inhaler’ with the Easyhaler®: an innovative dry powder inhaler. Clin Drug Investig. 2006;26(4):175–83.

    Article  CAS  PubMed  Google Scholar 

  9. Vidgren M, Silvasti M, Vidgren P, et al. Easyhaler® multiple dose powder inhaler: practical and effective alternative to the pressurized MDI. Aer Sci Technol. 1995;22(4):335–45.

    Article  CAS  Google Scholar 

  10. Reddy SC, Swain K, Shivakumar HG, et al. Past and present trends of drug powder inhaler devices: a review. J Drug Deliv Ther. 2012;4(1):97–107.

    Google Scholar 

  11. Lähelmä S, Vahteristo M, Metev H, et al. Equivalent bronchodilation with budesonide/formoterol combination via Easyhaler and Turbuhaler in patients with asthma. Respir Med. 2016;120:31–5.

    Article  PubMed  Google Scholar 

  12. Gálffy G, Mezei G, Németh G, et al. Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPD. Drugs R D. 2013;13(3):215–22.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Hantulik P, Wittig K, Henschel Y, et al. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany. Pneumonol Alergol Pol. 2015;83(5):365–77.

    Article  PubMed  Google Scholar 

  14. Ahonen A, Leinonen M, Ranki-Pesonen M. Patient satisfaction with Easyhaler® compared with other inhalation systems in the treatment of asthma: a meta-analysis. Curr Ther Res Clin Exp. 2000;61(2):61–73.

    Article  Google Scholar 

  15. Tukiainen H, Rytilä P, Hämäläinen KM, et al. Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients. Respir Med. 2002;96(4):221–9.

    Article  CAS  PubMed  Google Scholar 

  16. Malmberg LP, Rytilä P, Happonen P, et al. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis. 2010;5:257–62.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Haikarainen J, Selroos O, Löytänä T, et al. Budesonide/formoterol Easyhaler®: performance under simulated real-life conditions. Pulm Ther. 2017. doi:10.1007/s41030-016-0025-z.

    Google Scholar 

  18. Bufomix Easyhaler 160 micrograms/4.5 micrograms. Dublin: Orion Pharma (Ireland) Ltd; 2016.

  19. Bufomix Easyhaler 320 micrograms/9 micrograms. Dublin: Orion Pharma (Ireland) Ltd; 2016.

  20. Lähelmä S, Sairanen U, Haikarainen J, et al. Equivalent lung dose and systemic exposure of budesonide/formoterol combination via Easyhaler and Turbuhaler. J Aerosol Med Pulmon Drug Deliv. 2015;28(6):462–73.

    Article  Google Scholar 

  21. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337(20):1405–11.

    Article  CAS  PubMed  Google Scholar 

  22. Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J. 2001;18(2):262–8.

    Article  PubMed  Google Scholar 

  23. Pohunek P, Kuna P, Jorup C, et al. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatr Allergy Immunol. 2006;17(6):458–65.

    Article  PubMed  Google Scholar 

  24. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006;368(9537):744–53.

    Article  CAS  PubMed  Google Scholar 

  25. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;4:CD007313.

    Google Scholar 

  26. Edwards SJ, von Maltzahn R, Naya IP, et al. Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. Int J Clin Pract. 2010;64(5):619–27.

    Article  CAS  PubMed  Google Scholar 

  27. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912–9.

    Article  CAS  PubMed  Google Scholar 

  28. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81.

    Article  CAS  PubMed  Google Scholar 

  29. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;3:CD010844.

    Google Scholar 

  30. Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8:CD006826.

    Google Scholar 

  31. van Boven JFM, de Jong-van den Berg LT, Vegter S. Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis. Drug Saf. 2013;36(4):231–6.

    Article  PubMed  Google Scholar 

  32. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.

    Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: S.A. Antoniu, Department of Preventive Medicine and Interdisciplinarity, Medicine-Palliative Care Nursing, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India; J.F.M. van Boven, Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Gillian M. Keating

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Ethics declarations

Disclosure

The preparation of this review was not supported by any external funding. G. Keating is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest. During the peer review process, the manufacturer of the budesonide/formoterol Easyhaler® was offered an opportunity to comment on the article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keating, G.M. Budesonide/formoterol Easyhaler®: a guide to its use in asthma and chronic obstructive pulmonary disease. Drugs Ther Perspect 33, 95–101 (2017). https://doi.org/10.1007/s40267-017-0378-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-017-0378-x

Keywords

Search

Navigation